Cian Healthcare, a company in the Pharmaceuticals industry, reported revenue of ₹12 crore and a net loss of ₹1.00 crore for the September 2026 quarter.
Cian Healthcare (BSE: CHCL) closed at ₹44.10 on 20 Nov 2026. Its market capitalisation is ₹110 crore.
Cian Healthcare Ltd is a BSE-SME listed pharmaceutical-formulations manufacturer with own /franchise brands, third-party manufacturing, institutional/government supply and exports. It makes tablets, capsules, soft-gels, liquid orals, ointments/creams, sachets and cosmetics across gynaecology, haematinic, cardio-diabetic, orthopaedic, paediatric, derma-cosmetic, antibiotic, CNS, vitamins and nutrients. The company exited CIRP under new promoter control in FY26
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.